Basil Rigas

Department of Preventive Medicine, Stony Brook University

Research Area

Biography

Basil Rigas has not added Biography.
If you are Basil Rigas and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 2	Year
Publication title Cited by 12	2020
Publication title Cited by 9	2020

Other Publications

Article	Year
Nitric oxide-donating aspirin induces apoptosis in human colon cancer cells through induction of oxidative stress. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 16282376	2005
The use of nitric oxide-donating nonsteroidal anti-inflammatory drugs in the chemoprevention of colorectal neoplasia. Current opinion in gastroenterology\| PubMed ID: 17133086	2007
Development of novel agents based on nitric oxide for the control of colon cancer. Acta pharmacologica Sinica\| PubMed ID: 17723176	2007
The novel phenylester anticancer compounds: Study of a derivative of aspirin (phoshoaspirin). International journal of oncology\| PubMed ID: 18097547	2008
NO-donating NSAIDs and cancer: an overview with a note on whether NO is required for their action. Nitric oxide : biology and chemistry\| PubMed ID: 18486630	2008
A potentiometric protein sensor built with surface molecular imprinting method. Biosensors & bioelectronics\| PubMed ID: 18514502	2008
NO-Donating NSAIDs, PPARdelta, and Cancer: Does PPARdelta Contribute to Colon Carcinogenesis? PPAR research\| PubMed ID: 18528523	2008
NO-donating aspirin inhibits angiogenesis by suppressing VEGF expression in HT-29 human colon cancer mouse xenografts. Carcinogenesis\| PubMed ID: 18544566	2008
Nitric oxide-donating aspirin inhibits the growth of pancreatic cancer cells through redox-dependent signaling. Cancer letters\| PubMed ID: 18805632	2009
Pharmacokinetic and pharmacodynamic study of NO-donating aspirin in F344 rats. International journal of oncology\| PubMed ID: 18813794	2008
The thioredoxin system mediates redox-induced cell death in human colon cancer cells: implications for the mechanism of action of anticancer agents. Cancer research\| PubMed ID: 18922898	2008
Chemopreventive agents induce oxidative stress in cancer cells leading to COX-2 overexpression and COX-2-independent cell death. Carcinogenesis\| PubMed ID: 18952595	2009
Food components, alternative medicine, and cancer: progress and promise. Nutrition and cancer\| PubMed ID: 19003574	2008
Phosphoaspirin (MDC-43), a novel benzyl ester of aspirin, inhibits the growth of human cancer cell lines more potently than aspirin: a redox-dependent effect. Carcinogenesis\| PubMed ID: 19136474	2009
Regulation of peroxisome proliferator-activated receptor-beta/delta by the APC/beta-CATENIN pathway and nonsteroidal antiinflammatory drugs. Molecular carcinogenesis\| PubMed ID: 19415698	2009
The differential cell signaling effects of two positional isomers of the anticancer NO-donating aspirin. International journal of oncology\| PubMed ID: 19724920	2009
Annexin 1 induced by anti-inflammatory drugs binds to NF-kappaB and inhibits its activation: anticancer effects in vitro and in vivo. Cancer research\| PubMed ID: 20215502	2010
Phospho-sulindac (OXT-328), a novel sulindac derivative, is safe and effective in colon cancer prevention in mice. Gastroenterology\| PubMed ID: 20600034	2010
Phospho-sulindac (OXT-922) inhibits the growth of human colon cancer cell lines: a redox/polyamine-dependent effect. Carcinogenesis\| PubMed ID: 20627873	2010
Protein nitration and nitrosylation by NO-donating aspirin in colon cancer cells: Relevance to its mechanism of action. Experimental cell research\| PubMed ID: 21406194	2011
Phospho-ibuprofen (MDC-917) is a novel agent against colon cancer: efficacy, metabolism, and pharmacokinetics in mouse models. The Journal of pharmacology and experimental therapeutics\| PubMed ID: 21422165	2011
Phospho-sulindac (OXT-328) combined with difluoromethylornithine prevents colon cancer in mice. Cancer prevention research (Philadelphia, Pa.)\| PubMed ID: 21464038	2011
Oxidative stress mediates through apoptosis the anticancer effect of phospho-nonsteroidal anti-inflammatory drugs: implications for the role of oxidative stress in the action of anticancer a... The Journal of pharmacology and experimental therapeutics\| PubMed ID: 21646387	2011
Structure-activity relationship study of novel anticancer aspirin-based compounds. Molecular medicine reports\| PubMed ID: 21805049	2011
Chemotherapeutic properties of phospho-nonsteroidal anti-inflammatory drugs, a new class of anticancer compounds. Cancer research\| PubMed ID: 22025561	2011
Sterically stabilized liposomes incorporating the novel anticancer agent phospho-ibuprofen (MDC-917): preparation, characterization, and in vitro/in vivo evaluation. Pharmaceutical research\| PubMed ID: 22072052	2012
Carboxylesterases 1 and 2 hydrolyze phospho-nonsteroidal anti-inflammatory drugs: relevance to their pharmacological activity. The Journal of pharmacology and experimental therapeutics\| PubMed ID: 22085648	2012
Phospho-ibuprofen (MDC-917) suppresses breast cancer growth: an effect controlled by the thioredoxin system. Breast cancer research : BCR\| PubMed ID: 22293394	2012
Preclinical predictors of anticancer drug efficacy: critical assessment with emphasis on whether nanomolar potency should be required of candidate agents. The Journal of pharmacology and experimental therapeutics\| PubMed ID: 22448039	2012
Regioselective oxidation of phospho-NSAIDs by human cytochrome P450 and flavin monooxygenase isoforms: implications for their pharmacokinetic properties and safety. British journal of pharmacology\| PubMed ID: 22489789	2012
Phosphosulindac (OXT-328) selectively targets breast cancer stem cells in vitro and in human breast cancer xenografts. Stem cells (Dayton, Ohio)\| PubMed ID: 22653497	2012
Phospho-sulindac (OXT-328) inhibits the growth of human lung cancer xenografts in mice: enhanced efficacy and mitochondria targeting by its formulation in solid lipid nanoparticles. Pharmaceutical research\| PubMed ID: 22723123	2012
In vitro and in vivo metabolic studies of phospho-aspirin (MDC-22). Pharmaceutical research\| PubMed ID: 22782648	2012
Topical phospho-sulindac (OXT-328) is effective in the treatment of non-melanoma skin cancer. International journal of oncology\| PubMed ID: 22842609	2012
MC-12, an annexin A1-based peptide, is effective in the treatment of experimental colitis. PloS one\| PubMed ID: 22844504	2012
Nanodelivery strategies in cancer chemotherapy: biological rationale and pharmaceutical perspectives. Nanomedicine (London, England)\| PubMed ID: 23148540	2012
Platinum folate nanoparticles toxicity: cancer vs. normal cells. Toxicology in vitro : an international journal published in association with BIBRA\| PubMed ID: 23318730	2013
The anticancer effect of phospho-tyrosol-indomethacin (MPI-621), a novel phosphoderivative of indomethacin: in vitro and in vivo studies. Carcinogenesis\| PubMed ID: 23338686	2013
Comparative in vitro metabolism of phospho-tyrosol-indomethacin by mice, rats and humans. Biochemical pharmacology\| PubMed ID: 23399640	2013
Topically applied phospho-sulindac hydrogel is efficacious and safe in the treatment of experimental arthritis in rats. Pharmaceutical research\| PubMed ID: 23483440	2013
Aerosol administration of phospho-sulindac inhibits lung tumorigenesis. Molecular cancer therapeutics\| PubMed ID: 23645590	2013
Targeting mitochondrial STAT3 with the novel phospho-valproic acid (MDC-1112) inhibits pancreatic cancer growth in mice. PloS one\| PubMed ID: 23650499	2013
Curcumin enhances the lung cancer chemopreventive efficacy of phospho-sulindac by improving its pharmacokinetics. International journal of oncology\| PubMed ID: 23807084	2013
A novel Ras inhibitor (MDC-1016) reduces human pancreatic tumor growth in mice. Neoplasia (New York, N.Y.)\| PubMed ID: 24204197	2013
Phospho-sulindac inhibits pancreatic cancer growth: NFATc1 as a drug resistance candidate. International journal of oncology\| PubMed ID: 24284479	2014
Phospho-aspirin (MDC-22) inhibits breast cancer in preclinical animal models: an effect mediated by EGFR inhibition, p53 acetylation and oxidative stress. BMC cancer\| PubMed ID: 24575839	2014
The in vitro metabolism of phospho-sulindac amide, a novel potential anticancer agent. Biochemical pharmacology\| PubMed ID: 25044307	2014
Pegylation improves the pharmacokinetics and bioavailability of small-molecule drugs hydrolyzable by esterases: a study of phospho-Ibuprofen. The Journal of pharmacology and experimental therapeutics\| PubMed ID: 25047517	2014
A novel ibuprofen derivative with anti-lung cancer properties: synthesis, formulation, pharmacokinetic and efficacy studies. International journal of pharmaceutics\| PubMed ID: 25311177	2014
Phospho-aspirin-2 (MDC-22) inhibits estrogen receptor positive breast cancer growth both in vitro and in vivo by a redox-dependent effect. PloS one\| PubMed ID: 25369051	2014
Phospho-NSAIDs have enhanced efficacy in mice lacking plasma carboxylesterase: implications for their clinical pharmacology. Pharmaceutical research\| PubMed ID: 25392229	2015
Repurposing the antipsychotic trifluoperazine as an antimetastasis agent. Molecular pharmacology\| PubMed ID: 25552486	2015
The evolving role of nonsteroidal anti-inflammatory drugs in colon cancer prevention: a cause for optimism. The Journal of pharmacology and experimental therapeutics\| PubMed ID: 25589413	2015
Altered Interactions between the Gut Microbiome and Colonic Mucosa Precede Polyposis in APCMin/+ Mice. PloS one\| PubMed ID: 26121046	2015
NSAIDs and Colorectal Cancer Control: Promise and Challenges. Current pharmacology reports\| PubMed ID: 26688785	2015
The novel agent phospho-glycerol-ibuprofen-amide (MDC-330) inhibits glioblastoma growth in mice: an effect mediated by cyclin D1. Carcinogenesis\| PubMed ID: 26905586	2016
Phospho-Aspirin (MDC-22) Prevents Pancreatic Carcinogenesis in Mice. Cancer prevention research (Philadelphia, Pa.)\| PubMed ID: 27138793	2016
Phospho-valproic acid inhibits pancreatic cancer growth in mice: enhanced efficacy by its formulation in poly-(L)-lactic acid-poly(ethylene glycol) nanoparticles. International journal of oncology\| PubMed ID: 28849098	2017
Alkaline Ceramidase 1 Protects Mice from Premature Hair Loss by Maintaining the Homeostasis of Hair Follicle Stem Cells. Stem cell reports\| PubMed ID: 29056331	2017
Phosphosulindac is efficacious in an improved concanavalin A-based rabbit model of chronic dry eye disease. Translational research : the journal of laboratory and clinical medicine\| PubMed ID: 29702077	2018
[Corrigendum] Phospho‑valproic acid inhibits pancreatic cancer growth in mice: Enhanced efficacy by its formulation in poly‑(L)‑lactic acid‑poly(ethylene glycol) nanoparticles. International journal of oncology\| PubMed ID: 30320367	2018
The Chemoprevention of Ovarian Cancer: the Need and the Options. Current pharmacology reports\| PubMed ID: 30363743	2018
The ocular pharmacokinetics and biodistribution of phospho-sulindac (OXT-328) formulated in nanoparticles: Enhanced and targeted tissue drug delivery. International journal of pharmaceutics\| PubMed ID: 30597269	2019
A New Rabbit Model of Chronic Dry Eye Disease Induced by Complete Surgical Dacryoadenectomy. Current eye research\| PubMed ID: 30983427	2019
Phospho-valproic acid (MDC-1112) suppresses glioblastoma growth in preclinical models through the inhibition of STAT3 phosphorylation. Carcinogenesis\| PubMed ID: 30994173	2019
Correction: The Chemoprevention of Ovarian Cancer: the Need and the Options. Current pharmacology reports\| PubMed ID: 31187022	2018
NSAID-induced corneal melt: Clinical importance, pathogenesis, and risk mitigation. Survey of ophthalmology\| PubMed ID: 31306671	2020
Phospho-valproic acid (MDC-1112) reduces pancreatic cancer growth in patient-derived tumor xenografts and KPC mice: enhanced efficacy when combined with gemcitabine. Carcinogenesis\| PubMed ID: 31584613	2019